Skip to article frontmatterSkip to article content
Site not loading correctly?

This may be due to an incorrect BASE_URL configuration. See the MyST Documentation for reference.

Neoplasms Drilldown Analysis Report

Overview

This report summarizes the findings from a drilldown analysis of the gender gap in cancer (neoplasm) mortality, using data from the IHME Global Burden of Disease (GBD) 2023. We analyzed the “Deaths per 100,000” measure attributable to risk factors (Behavioral, Metabolic, and Environmental/Occupational) across three locations: the United States, Iceland, and the OECD Total.

Key Findings

1. Dominant Causes of the Gender Gap (USA vs. Iceland vs. OECD)

The mortality gap (Male Rate - Female Rate) is driven by different cancers depending on the location.

NeoplasmUSA GapIceland GapOECD Gap
Tracheal, bronchus, and lung cancer+18.40+4.94+42.80
Liver cancer+5.68+5.88+6.72
Esophageal cancer+5.69+4.93+5.52
Breast cancer-12.40-11.40-12.50
Cervical cancer-4.19-3.02-5.42
Colon and rectum cancer+2.07+2.39+3.44

Geographical Variations:

2. Risk Factor Contributions

Across all locations, the IHME data attributes these gaps primarily to:

3. Missing Data on Specific Cancers

We observed that several cancers—including Brain/CNS cancer, Eye cancer, Hodgkin lymphoma, and Testicular cancer—have no risk factor attribution in the GBD dataset. This is because the GBD framework does not currently recognize any of the 87 modifiable risk factors as having a “convincing or suggestive” causal link to these outcomes. Consequently, while these cancers contribute to the total neoplasm gap, they do not show up in this attributable drilldown.

Detailed Results (United States)

The following tables provide more granular detail for the United States. In the US, the sum of all “positive” gaps (where male mortality is higher) is 45.70 deaths per 100,000, while the sum of all “negative” gaps (where female mortality is higher) is -21.93 deaths per 100,000.

Neoplasm Gaps by Cancer Type

This table shows the death rates (per 100,000) for males and females across 34 cancer types, sorted by the absolute difference.

NeoplasmMale RateFemale RateDifference
Tracheal, bronchus, and lung cancer5334.618.4
Breast cancer0.074112.5-12.4
Esophageal cancer7.091.415.69
Liver cancer10.54.845.68
Cervical cancer04.19-4.19
Uterine cancer03.36-3.36
Bladder cancer3.381.052.32
Colon and rectum cancer18.216.12.07
Ovarian cancer01.83-1.83
Leukemia3.932.231.7
Pancreatic cancer9.868.171.69
Kidney cancer2.881.241.65
Larynx cancer2.010.4131.6
Prostate cancer1.2801.28
Lip and oral cavity cancer1.460.4570.999
Other pharynx cancer1.090.220.874
Mesothelioma1.10.3820.722
Stomach cancer1.270.630.643
Non-Hodgkin lymphoma0.7220.5560.166
Multiple myeloma0.6160.4750.142
Gallbladder and biliary tract cancer0.2590.351-0.0925
Nasopharynx cancer0.1210.03260.0881
Thyroid cancer0.1290.136-0.00771
Brain and central nervous system cancer000
Eye cancer000
Hodgkin lymphoma000
Malignant neoplasm of bone and articular cartilage000
Malignant skin melanoma000
Neuroblastoma and other peripheral nervous cell tumors000
Non-melanoma skin cancer000
Other malignant neoplasms000
Other neoplasms000
Soft tissue and other extraosseous sarcomas000
Testicular cancer000

Risk Factor Attribution

This table shows how the gender gap for each cancer type is allocated across the three risk categories: Behavioral, Environmental/Occupational, and Metabolic.

NeoplasmGap_Behavioral risksGap_Environmental/occupational risksGap_Metabolic risksTotal Gap
Tracheal, bronchus, and lung cancer6.7711.10.50318.4
Breast cancer-7.120-5.32-12.4
Esophageal cancer5.69005.69
Liver cancer4.5401.145.68
Cervical cancer-4.1900-4.19
Uterine cancer00-3.36-3.36
Bladder cancer1.5700.7532.32
Colon and rectum cancer1.0800.9852.07
Ovarian cancer0-0.463-1.37-1.83
Leukemia1.290.001560.4081.7
Pancreatic cancer1.0400.6561.69
Kidney cancer0.5820.0008651.071.65
Larynx cancer1.350.24901.6
Prostate cancer1.28001.28
Lip and oral cavity cancer0.999000.999
Other pharynx cancer0.874000.874
Mesothelioma00.72200.722
Stomach cancer0.643000.643
Non-Hodgkin lymphoma000.1660.166
Multiple myeloma000.1420.142
Gallbladder and biliary tract cancer00-0.0925-0.0925
Nasopharynx cancer0.08760.0004600.0881
Thyroid cancer00-0.00771-0.00771
Brain and central nervous system cancer0000
Eye cancer0000
Hodgkin lymphoma0000
Malignant neoplasm of bone and articular cartilage0000
Malignant skin melanoma0000
Neuroblastoma and other peripheral nervous cell tumors0000
Non-melanoma skin cancer0000
Other malignant neoplasms0000
Other neoplasms0000
Soft tissue and other extraosseous sarcomas0000
Testicular cancer0000

Conclusion

The “attributable” gender gap in cancer is largely a story of Behavioral and Metabolic risks. The USA and OECD gaps are dominated by lung cancer (Behavioral/Smoking), while Iceland’s gap is more evenly distributed across liver, esophageal, and lung cancers. In all regions, breast cancer remains the primary driver of higher female cancer mortality.